Sign in

Alliance for Advancing Bioelectronic Medicine

AABM News Roundup: January 2021

Photo by Robina Weermeijer on Unsplash

Lead Stories: January 2021

Chad Bouton of the Feinstein Institutes describes how his lab worked to create a completely non-invasive neural bypass system in IEEE Spectrum on January 26th:

“My group’s particular quest is to crack the neural codes related to movement and sensation so we can develop new ways to treat the millions of people around the world who are living with paralysis — 5.4 million people in the United States alone.”

For more about non-invasive neural bypass, see: Brain Implants and Wearables Let Paralyzed People Move Again

Medtronic is optimistic about results from a recent study on…


AABM News Roundup: April 2021

Photo by David Cassolato from Pexels

Lead Stories: April 2021

There’s a growing focus on equity across the entire healthcare field. In neuromodulation, unfortunately, disparities are emerging in access to deep brain stimulation (DBS) therapy for chronic pain. Two researchers, Myrdalis Diaz-Ramirez and Stephanie Venterpool, were interviewed by NeuroNews in April and explained the issue — and how to address it:

“The tendency is for neuromodulation therapies to be offered or more accessible to Caucasian men, with private insurance, fewer comorbidities, seen at higher volume hospitals, and with higher income household. … African American patients who met characteristics for DBS received the procedure much less…


AABM News Roundup: March 2021

Photo by Robina Weermeijer on Unsplash

Lead Stories: March 2021

Researchers from the Feinstein Institutes and GE have discovered a potential non-pharmacological treatment for diabetes and obesity: ultrasound stimulation of the liver. Studies on mice are promising, as explained by one of the authors of the study, Sangeeta Chavan:

“We have extensive data to show that when you do liver stimulation you improve the glucose levels in these animals, and you improve the response to insulin. …


AABM News Roundup: January 2021

Photo by Robina Weermeijer on Unsplash

Lead Stories: January 2021

Chad Bouton of the Feinstein Institutes describes how his lab worked to create a completely non-invasive neural bypass system in IEEE Spectrum on January 26th:

“My group’s particular quest is to crack the neural codes related to movement and sensation so we can develop new ways to treat the millions of people around the world who are living with paralysis — 5.4 million people in the United States alone.”

For more about non-invasive neural bypass, see: Brain Implants and Wearables Let Paralyzed People Move Again

Medtronic is optimistic about results from a recent study on…


AABM News Roundup: December 2020

Lead Stories: December 2020

Researchers at Lehigh University have made an important breakthrough: physiological evidence that a pervasive neuromodulation system — a group of neurons that controls the way more specialized neurons function — strongly influences how a key auditory region of our brain processes sound. As R. Michael Burger, professor of neuroscience and a co-author of the study, explains:

“this study will likely bring new attention in the field to the ways in which circuits like this, widely considered a ‘simple’ one, are in fact highly complex and subject to modulatory influence like higher regions of the brain.”


AABM News Roundup: November 2020

Photo by Charles Postiaux on Unsplash

Lead Stories: November 2020

Sky Medical Technology’s CEO, Bernard Ross, discusses how bioelectronic medicine can offer solutions to critical public health challenges in the U.K.:

“Medical devices can significantly reduce NHS waiting lists by making treatment pathways much more efficient. For example, wearable bioelectronic therapy, a medical device innovation already used in many NHS Trusts, sends a small electrical pulse down the lower limbs, activating the calf muscles to increase blood flow in the deep veins, to address life threatening blood clots and pre and post-operative swelling following orthopaedic surgery.”

Read Mr. Ross’s complete op-ed here: How can technology…


AABM News Roundup: October 2020

Photo by Lena Balk on Unsplash

Lead Stories: October 2020

In the last month, several prominent European companies in the neuromodulation and neurostimulation space have received major investments. This influx of cash reflects the impressive growth of the field:

“Devices are getting more sophisticated, and new disease indications are opening up…the technology has now reached a point where there are effective examples of its use on the market.”

To learn more about how the field is drawing the attention of investors, see: Investment Is Pouring Into Neuromodulation Treatments, LabioTech.edu, October 7, 2020

Cala Health received breakthrough device designation for its Cala Trio treatment for action…


AABM News Roundup: September 2020

Photo by Jessica Radanavong on Unsplash

Lead Stories: September 2020

The FDA has granted breakthrough designation to SetPoint Medical’s novel bioelectronic platform to treat rheumatoid arthritis. SetPoint’s CEO, Dr. Murthy V. Simhambhatla, hailed the regulatory clearance:

“This is a significant milestone for SetPoint that will enable interactive communication with the FDA, priority regulatory review for the U.S. market, as well as support reimbursement and patient access upon FDA approval.”

For more information, see: SetPoint Medical Receives FDA Breakthrough Designation for its Novel Bioelectronic Platform, Press Release, October 6, 2020

The United States Department of Veterans Affairs is funding a study of a VNS treatment that…


AABM News Roundup: August 2020

Photo by Dušan veverkolog on Unsplash

Lead Stories: August 2020

Neurolief’s wearable, non-invasive, multi-channel brain neuromodulation device Relivion was designated as a “breakthrough device” by the FDA. The device is designed as “an adjunctive treatment to pharmaceutical management of major depressive disorder (MDD) in adults.” Following the designation, Neurolief chairman Chris Richardson said:

“Gaining FDA recognition of our potential to substantially impact an area of unmet need bolsters our upcoming Relivion DP major depression pivotal study, and brings us one step closer to reaching people who desperately need this new treatment.”

For further details, see: Neurolief wins FDA breakthrough nod for wearable neuromod for depression


AABM News Roundup: July 2020

Photo by Clique Images on Unsplash

Lead Stories: July 2020

Abbot recently received FDA approval for a new smartphone app that lets people personalize their own neuromodulation therapies, including regimens for chronic pain and movement disorders like Parkinson's. Following the approval, Keith Boettiger, vice president of Abbott’s neuromodulation business, said:

“Patients are seeking digital options to better engage with their healthcare providers and manage their chronic conditions remotely — and this has never been more evident than in today’s pandemic where virtual care is necessary.”

To learn more, see: Abbott receives FDA approval for neurostimulator-controlling iPhone app for personalizing therapies for pain, Parkinson’s disease, FierceBiotech…

Alliance for Advancing Bioelectronic Medicine

Committed to accelerating the development and uptake of bioelectronic medicine.

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store